It has been shown that high levels of chemokines CCL3, CCL4, and CXCL8 in pre-treatment tumor specimens were associated with worse patient overall survival after anti-CTLA4 and Carboplatin/paclitaxel treatment in melanoma (120). The gene discussed is CCL4; the disease is melanoma.